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Introduction
Breast cancer is responsible for the largest proportion of can-
cer diagnosis among young adult women.1 The burden of 
breast cancer in young women appears to be on the rise and is 
of even more importance in certain parts of the world.2–4 A 
significant proportion of young women with early breast can-
cer are candidates to receive chemotherapy as part of their 
treatment considering both the higher incidence of develop-
ing aggressive tumor subtypes and the tendency to be diag-
nosed at a more advanced stage.5,6 In premenopausal women, 
one of the potential drawbacks of chemotherapy use is repre-
sented by its possible gonadal damage.7 The risk of developing 
chemotherapy-induced premature ovarian insufficiency (POI) 
is of particular concern for young patients considering the 
potential significant negative impact on their quality of life, 
being associated with menopause-related symptoms, psycho-
social issues, health problems, and infertility.8 In addition, 
since many women are now choosing to defer motherhood, a 
considerable proportion of them has not completed their fam-
ily plans yet at the time of cancer diagnosis, but wish to do it 
after treatment completion.9 Recent data have helped to reas-
sure patients and physicians on the safety of conceiving after 
prior history of breast cancer.10–13 Therefore, discussing fertil-
ity and pregnancy-related issues with all newly diagnosed 
young patients is now considered mandatory before the initia-
tion of anticancer treatments.14–18
For women willing to preserve fertility, in order to have 
higher chances of conception after completing their treatment, 
embryo and oocyte cryopreservation are standard strategies 
and the first options to be proposed.14–18 However, these tech-
niques do no avoid the risk of chemotherapy-induced POI 
with its associated psychosocial and menopause-related con-
cerns beyond infertility. Temporary ovarian suppression 
obtained pharmacologically with the administration of a gon-
adotropin-releasing hormone agonist (GnRHa) during chem-
otherapy has been specifically developed as a method to 
counteract chemotherapy-induced gonadotoxicity with the 
main goal of diminishing the risk of POI. Despite the existence 
of more than 30 years of research, the role of this strategy has 
remained highly debated.19–27 In recent years, important 
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clinical evidence has become available on the efficacy and 
safety of temporary ovarian suppression with GnRHa during 
chemotherapy and this strategy is now recommended for 
premenopausal breast cancer patients who are candidates to 
systemic cytotoxic therapy.16,18,28
In this article, we present an overview about the role of tem-
porary ovarian suppression with GnRHa during chemotherapy 
in breast cancer patients by addressing the available clinical 
evidence with the aim of identifying both the best candidates 
for the use of this strategy and the still existing gray zones 
requiring further investigation.
Clinical Evidence on the Role of GnRHa During 
Chemotherapy in Breast Cancer
Following the promising pivotal experimental studies by Ataya 
and colleagues in the 1980s,29 the clinical development to 
demonstrate the protective gonadal effect of administering 
GnRHa during chemotherapy rapidly started.30 Notably, most 
of the evidence on the topic derives from studies conducted in 
the breast cancer setting, with more limited data for women 
with other solid tumors or with hematological malignancies.30
Initially, the potential protective gonadal effect of GnRHa 
use during chemotherapy was investigated in several observa-
tional and single-arm phase II trials.31 Overall, these studies 
suggested that the majority (70%-100%) of women treated 
with GnRHa during systemic cytotoxic therapy did not experi-
ence chemotherapy-induced POI, and more than 50 post-
treatment pregnancies were described.31 Following these 
promising results, several randomized clinical trials were exe-
cuted and pooled in different meta-analyses.
Randomized clinical trials in breast cancer patients
The largest amount of data from randomized clinical trials on 
the clinical efficacy of temporary ovarian suppression with 
GnRHa during chemotherapy as a strategy to preserve ovarian 
function and potential fertility is available for premenopausal 
women with breast cancer. Fourteen randomized clinical trials 
have been performed in this setting (Table 1).32–47
Patients included in these studies had a median age close 
to 40 years and often received anthracycline- and cyclophos-
phamide-based chemotherapy. Goserelin was the GnRHa 
administered in the majority of the studies (n = 8), followed by 
triptorelin (n = 5), and leuprolide acetate (n = 1). Most of these 
studies were also characterized by the following features: (1) 
small sample size (ie, less than 100 randomized patients); (2) 
definition of chemotherapy-induced POI based only on men-
strual function after treatment; (3) variable timing for POI 
evaluation ranging from 6 months up to more than 5 years 
after chemotherapy completion. Notably, the largest trials 
providing the highest level of evidence on this regard 
(PROMISE-GIM6,37,44 POEMS/SWOG S0230,43,47 and 
Anglo Celtic Group OPTION45) were characterized by a 
large sample size (more than 200 included patients) and 
defined chemotherapy-induced POI using a composite end-
point (ie, amenorrhea and postmenopausal hormonal levels) 
not earlier than 1 year after the end of chemotherapy.
With the exception of 4 trials, all the other studies showed 
that concurrent use of GnRHa during chemotherapy is associ-
ated with a significant reduction in POI risk. Specifically, the 3 
largest trials (PROMISE-GIM6,37,44 POEMS/SWOG 
S0230,43,47 and Anglo Celtic Group OPTION45) reported 
very similar results: the use of GnRHa during chemotherapy 
was associated with a significant 15% absolute reduction (from 
approximately 25% to less than 10%) in POI rates after chem-
otherapy. The only large trial showing no protective effect was 
the study by Zhang and colleagues; notably, in this trial, all 
patients received GnRHa and were randomized between its 
sequential or simultaneous administration with chemother-
apy.46 Therefore, the results on POI rates after chemotherapy 
should be considered with cautious also considering that 
patients in the two treatment arms received a different duration 
of GnRHa treatment (ranging between 2 and 5 years), the 
timepoint for the assessment of POI was highly variable, and 
only amenorrhea data were reported (despite the primary end-
point of POI was defined with a composite endpoint of amen-
orrhea and postmenopausal hormonal levels).25
Despite the more consistent results in terms of protective 
effects in reducing POI risk, the evidence on the fertility pres-
ervation potential of temporary ovarian suppression with 
GnRHa during chemotherapy remains more limited. The 
POEMS/SWOG S0230 trial was the only study with post-
treatment pregnancies as a pre-planned secondary end-
point.43,47 Notably, none of the studies was powered to detect 
differences in this outcome, wish for conceiving was not an 
inclusion criteria, and follow-up at the time of reporting chem-
otherapy-induced POI (ie, their primary endpoint) was rela-
tively short. Therefore, they had limited possibility to assess 
post-treatment pregnancies considering both the inclusion of 
premenopausal patients older than 40 years at the time of diag-
nosis, as well as the fact that an adequate follow-up time to 
record post-treatment pregnancies is of particular importance 
for breast cancer patients who are often also candidates to 
5-10 years of adjuvant endocrine therapy.16,48–51 Nevertheless, 
taking into account these limitations, the POEMS/SWOG 
S0230 trial was the only trial among those reporting on post-
treatment pregnancies showing that the use of temporary ovar-
ian suppression with GnRHa during chemotherapy was 
associated with a significant higher number of patients con-
ceiving after the end of treatment.43,47 More post-treatment 
pregnancies in patients treated with GnRHa during chemo-
therapy were also observed in the updated analysis of the 
PROMISE-GIM6 trial44 and the Anglo Celtic Group 
OPTION study,45 but the absolute numbers were small and no 
significant difference could be detected. Notably, none of these 
analyses were adjusted for pregnancy desire (this information 
was available only for a minority of randomized patients).
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When discussing the role of temporary ovarian suppression 
with GnRHa during systemic cytotoxic therapy in breast can-
cer patients and particularly in those with estrogen receptor-
positive disease, two safety concerns have been raised: a 
potential antagonism with the concurrent administration of an 
endocrine agent during chemotherapy and the possible nega-
tive prognostic effect of preventing POI occurrence.52 However, 
recent evidence has helped to clarify and reassure physicians 
and patients on these two issues.
Regarding the potential antagonism between endocrine 
agents and chemotherapy, it should be noted that this has 
been shown only for tamoxifen in preclinical studies,53 but it 
has not been confirmed in clinical trials.54 No data are avail-
able to suggest a potential negative interaction between 
Table 1. Randomized clinical trials in breast cancer patients assessing the role of temporary ovarian suppression with 
gonadotropin-releasing hormone agonist during chemotherapy.








Li et al32 Amenorrhea (12 months) 63  • POI rate: 32.1% vs 
53.1% (P = .027)
YES
Badawy et al33 Amenorrhea and no 
resumption of ovulation 
(8 months)
78  • POI rate: 11.4% vs 
66.6% (P < .001)
YES
Sverrisdottir et al34 Amenorrhea (up to 
36 months)
94  • POI rate: 64% (93%) vs 
90% (87%) (P = .006)
YES
Gerber et al35 Amenorrhea (6 months) 60  • POI rate: 30% vs 43.3% 
(P = .142)
 • Pregnancies: 1 vs 1
NO
Sun et al36 Amenorrhea (12 months) 21  • POI rate: 27.3% vs 
50.0% (P = .039)
YES
Del Mastro et al37 and 
Lambertini et al44
Amenorrhea and post-
menopausal FSH and E2 
levels (12 months)
281  • POI rate: 8.9% vs 
25.9% (P < .001)
 • Pregnancies: 8 vs 3 
(P = .20)
YES
Munster et al38 Amenorrhea (24 months) 49  • POI rate: 15% vs 14% 
(P = .32)
 • Pregnancies: 0 vs 2
NO
Elgindy et al39 Amenorrhea (12 months) 100  • POI rate: 20%/16% vs 
20%/20% 
(P = 1.00/P = .71)
 • Pregnancies: 2 vs 1
NO
Song et al40 Amenorrhea and post-
menopausal FSH and E2 
levels (12 months)
183  • POI rate: 16.9% vs 
28.7% (P < .01)
YES
Jiang et al41 Amenorrhea (NR) 21  • POI rate: 10.0% vs 
45.5% (P = .05)
YES
Karimi-Zarchi et al42 Amenorrhea (6 months) 42  • POI rate: 9.5% vs 
66.7% (P < .001)
YES
Moore et al43 and 
Moore et al47
Amenorrhea and post-
menopausal FSH levels 
(24 months)
218  • POI rate: 8% vs 22% 
(P = .04)
 • Pregnancies: 23 vs 13 
(P = .04)
YES
Leonard et al45 Amenorrhea and post-
menopausal FSH levels 
(between 12 and 
24 months)
221  • POI rate: 18.5% vs 
34.8% (P = .048)
 • Pregnancies: 7 vs 5
YES
Zhang et al46 Amenorrhea and post-
menopausal FSH and E2 
levels (36-72 months)
216  • POI rate: 23.1% vs 
22.8% (P = .969)
NO
Abbreviations: E2, estradiol; FSH, follicle-stimulating hormone; GnRHa, gonadotropin-releasing hormone agonist; NR, not reported; POI, premature 
ovarian insufficiency.
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ovarian suppression and chemotherapy. On the contrary, 
results from randomized clinical trials did not demonstrate 
any difference in the prognosis of patients who received 
chemotherapy with or without concurrent pharmacological 
or surgical ovarian suppression.55–57 This has recently been 
confirmed in the TEXT and SOFT trials showing similar 
survival outcomes with concurrent or sequential administra-
tion of GnRHa in premenopausal breast cancer patients with 
estrogen receptor-positive disease.58
Regarding the second safety issue, it is known that chemo-
therapy-induced POI has a strong positive prognostic value in 
premenopausal women with estrogen receptor-positive breast 
cancer.59,60 As shown in the SOFT trial, prolonging ovarian 
suppression for a total duration of 5 years in this setting is ben-
eficial,61 and it is endorsed by currently available guide-
lines.16,49,51 This concern can be addressed with the possibility 
to prolong the administration of GnRHa as part of adjuvant 
endocrine treatment. The two randomized clinical trials that 
investigated temporary ovarian suppression with GnRHa dur-
ing chemotherapy, also in patients with estrogen receptor-pos-
itive breast cancer and with sufficient follow-up to assess 
survival outcomes, confirmed the lack of negative prognostic 
impact for GnRHa administration during systemic cytotoxic 
therapy.44,46 However, in both studies, the majority of the 
patients with estrogen receptor-positive disease received 
GnRHa as part of their adjuvant endocrine therapy in the case 
of ovarian function resumption after chemotherapy.44,46 
Reassuring data on the safety of administering GnRHa during 
chemotherapy also in women with estrogen receptor-positive 
breast cancer have been reported in other large retrospective 
studies.62–64
Therefore, based on all these findings, it can be concluded 
that the administration of GnRHa during chemotherapy does 
not negatively interact with systemic cytotoxic therapy. 
However, it is preferable to prolong its use up to 5 years after 
diagnosis as adjuvant endocrine therapy in women with estro-
gen receptor-positive breast cancer.16,49,51
Meta-analysis of randomized clinical trials 
including breast cancer patients
Over the past years, the results from the available randomized 
clinical trials have been summarized in several meta-analyses 
(Table 2).65–82 Notably, the first meta-analyses included also 
prospective non-randomized studies. Eight of these meta-
analyses were restricted to breast cancer trials while the others 
also included patients with autoimmune diseases and/or hema-
tological malignancies and/or ovarian cancer.
A protective effect of temporary ovarian suppression with 
GnRHa during chemotherapy therapy in reducing POI risk 
was observed in all but two meta-analyses with a more pro-
nounced and clearer benefit observed in those that included 
only the trials conducted in the breast cancer setting. The most 
recent meta-analyses including a higher number of patients 
and the largest trials showed not only a reduction in the risk of 
chemotherapy-induced POI, but also a significantly higher 
rate of post-treatment pregnancies in premenopausal women 
treated with GnRHa during chemotherapy.
The largest meta-analysis performed to summarize the 
results of the breast cancer trials showed positive results.76 
When pooling the results from 12 randomized clinical trials 
including 1231 breast cancer patients, the use of temporary 
ovarian suppression with GnRHa during chemotherapy was 
associated with both reduced POI rates (15% absolute reduc-
tion [from 34% to 19%]; 64% relative reduction [odds ratio 
[OR] 0.36, 95% confidence interval [CI] 0.23-0.57]) and 
increased chances of post-treatment pregnancies (33 vs 19; 
OR 1.83, 95% CI 1.02-3.28).76 More recently, a meta-analy-
sis including individual patient-level data from 873 patients 
randomized in the 5 major breast cancer trials showed similar 
results.82 Chemotherapy-induced POI rate was 14.1% in 
patients who received GnRHa and 30.9% in the control 
group (adjusted OR 0.38, 95% CI 0.26-0.57). The protective 
effect of GnRHa administration was observed irrespectively 
of patients’ age at the time of treatment (including those older 
than 40 years), estrogen receptor status (including those with 
estrogen receptor-positive disease), type and duration of 
chemotherapy. In terms of fertility rates, 37 and 20 patients 
had at least one post-treatment pregnancy in the GnRHa and 
control groups, respectively (incidence rate ratio [IRR] 1.83, 
95% CI 1.06 to 3.15). In addition, concurrent use of GnRHa 
during chemotherapy was associated with no impact on dis-
ease-free survival (hazard ratio [HR], 1.01; 95% CI 0.72-
1.42) and a non-significant trend toward better overall 
survival (HR, 0.67; 95% CI 0.42-1.06). The safety of this 
approach was observed irrespectively of tumor estrogen 
receptor status.82
When considering the results from the meta-analyses that 
were not restricted to breast cancer trials, the protective effect 
of temporary ovarian suppression with GnRHa during chemo-
therapy was present in the overall population, but could not be 
observed for women with hematological malignancies. The 
largest meta-analysis, that also included lymphoma trials, 
pooled the results from 13 studies and a total of 1208 patients 
with breast cancer (n = 1099) and hematological malignancies 
(n = 109).80 Globally, GnRHa administration was associated 
with a significantly reduced risk of chemotherapy-induced 
POI (POI rate: 20% vs 34%; relative risk [RR] 0.60, 95% CI 
0.45-0.79), but this benefit did not persist in the subgroup 
analysis restricted to lymphoma patients (POI rate: 19% vs 
32%; RR 0.70, 95% CI 0.20-2.47). More women treated with 
GnRHa had a post-treatment pregnancy (57 vs 42; RR 1.43, 
95% CI 1.01-2.02), but the benefit was not observed in the 
subgroup of women with hematological malignancies (17 vs 
18; RR 1.13, 95% CI 0.66-1.93).80
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Table 2. Meta-analyses including randomized clinical trials in breast cancer patients assessing the role of temporary ovarian 
suppression with gonadotropin-releasing hormone agonist during chemotherapy.
AUTHORS INCLUDED DISEASES 










Autoimmune disease, HL 
and NHL
16a (681)  • POI: RR 0.26, 95% CI 0.14-0.49
 • POI (RCTs only): RR 0.55, 95% CI 
0.22-1.38
 • Pregnancies: 47 (22%) vs 25 (12%); RR 
1.51, 95% CI 1.01-2.28
 • Pregnancies (RCTs only): 2 (4%) vs 9 
(18%); RR 0.33, 95% CI 0.10-1.08
YES (NO in RCTs)
Kim et al66 Autoimmune disease, HL 
and NHL
11b (654)  • POI rate: 10% vs 53%; OR 10.57, 95% CI 
5.22-21.39
 • POI (RCTs only): 13% vs 57%; OR 5.76, 
95% CI 0.47-71.03
YES
Bedaiwy et al67 Ovarian cancer, and HL 6 (340)  • POI rate: 43% vs 65%; OR 3.46, 95% CI 
1.13-10.57
 • Pregnancies: 1 (2%) vs 4 (7%); OR 0.44, 
95% CI 0.07-2.59
YES (NO for 
pregnancy)
Chen et al68 Ovarian cancer and HL 4 (157)  • POI rate: 6% vs 55%; RR 1.90, 95% CI 
1.33-2.70
 • Pregnancies: 0 (0%) vs 2 (13%); RR 0.21, 
95% CI 0.01-4.09
YES (NO for 
pregnancy)
Yang et al69 - 5 (528)  • POI: RR 0.40, 95% CI 0.21-0.75
 • Pregnancies: RR 0.96, 95% CI 0.20-4.56
YES (NO for 
pregnancy)
Wang et al70 - 7 (677)  • POI: OR 2.83, 95% CI 1.52-5.25 YES
Sun et al71 Ovarian cancer, and HL 8 (621)  • POI rate: 10% vs 27%; RR 0.45, 95% CI 
0.22-0.92
 • Pregnancies: 6 (2%) vs 6 (3%); RR 0.93, 
95% CI 0.33-2.61
YES (NO for 
pregnancy)
Del Mastro et al72 Ovarian cancer, HL and 
NHL
9 (765)  • POI rate: 22% vs 37%; OR 0.43, 95% CI 
0.22-0.84
 • Pregnancies: 10 vs 3
YES
Vitek et al73 -c 4 (252)  • POI rate: 24% vs 27%; OR 1.47, 95% CI 
0.60-3.62
NO
Elgindy et al74 Ovarian cancer, HL and 
NHL
10 (907)  • POI rate: 32% vs 40%; RR 1.12, 95% CI 
0.99-1.27
 • Pregnancies: 30 (7%) vs 20 (5%); RR 
1.63, 95% CI 0.94-2.82
NO
Shen et al75 - 11 (1062)  • POI rate: 30% vs 45%; OR 2.57, 95% CI 
1.65-4.01
 • Pregnancies: 26 (9%) vs 16 (6%); OR 
1.77, 95% CI 0.92-3.40
YES (NO for 
pregnancy)
Lambertini et al76 - 12 (1231)  • POI rate: 19% vs 34%; OR 0.36, 95% CI 
0.23-0.57
 • Pregnancies: 33 (9%) vs 19 (6%); OR 
1.83, 95% CI 1.02-3.28
YES
Munhoz et al77 - 7 (856)  • POI rate at 6 months: 26% vs 43%; OR 
2.41, 95% CI 1.40-4.15
 • POI rate at 12-24 months: 26% vs 37%; 
OR 1.85, 95% CI 1.33-2.59
 • Pregnancies: OR 1.85, 95% CI 1.02-3.36
YES
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The Still Missing Evidence in the Field
Despite all the research efforts conducted over the past 30 years 
and the evidence on the protective effect of temporary ovarian 
suppression with GnRHa during chemotherapy shown in the 
recently published large trials, several gray zones remain in the 
field both overall and specifically for breast cancer patients.
First, it should be highlighted that the mechanisms by 
which GnRHa administration can protect ovarian function 
during chemotherapy are not yet fully elucidated.30,83 None of 
the biological hypotheses including gonadotropin suppression, 
decrease of follicular recruitment, reduction in ovarian blood 
flow or direct effects on the ovaries have been clearly demon-
strated by experimental studies.30 Notably, the majority of the 
experimental data has been obtained with in vivo studies in 
rodents (ie, the most studied model in reproductive biology). 
However, extrapolating the results obtained from these studies 
to humans remains hazardous. Therefore, additional well-con-
ducted research efforts in the field including species other than 
rodents are warranted in the next years.30
Second, despite the consistent results observed in the trials 
conducted in the breast cancer setting, limited evidence exists 
on the role of this strategy to counsel women diagnosed with 
other tumors. The four randomized trials performed in 
women with hematological malignancies showed no protec-
tive effect for temporary ovarian suppression with GnRHa 
during chemotherapy.84–88 However, it should be highlighted 
that all these studies had a small sample size with a total of 
approximately 150 patients when considered all together. 
Other large retrospective or prospective series have shown a 
potential protective effect of temporary ovarian suppression 
with GnRHa during chemotherapy in preserving ovarian 
function and potential fertility also in women with hemato-
logical malignancies.89–93 In women with solid tumors other 
than breast cancer, only one small randomized trial has 
assessed the role of temporary ovarian suppression with 
GnRHa during chemotherapy in 30 young patients with 
ovarian cancer.94 The study showed a significant reduction in 
the risk of chemotherapy-induced POI with the use of 
GnRHa during chemotherapy, but no information on post-
treatment pregnancies was reported.94
Third, limited evidence exists on the role of administering 
GnRHa during chemotherapy on patients’ ovarian reserve and 
on its long-term protective effect. Amenorrhea alone, as used in 
the majority of the randomized clinical trials that investigated 
this strategy, is not an optimal surrogate for defining POI devel-
opment.95 In fact, it has been shown that the use of chemo-
therapy can have a negative impact on a woman ovarian reserve 
leading to infertility and early menopause beyond the risk of 
acute POI.96 Irrespectively of the primary endpoint definition 
of chemotherapy-induced POI used in the different rand-
omized clinical trials conducted in this setting, none of them 
have reported age at menopause for patients who received 
chemotherapy with or without concurrent GnRHa. Long-term 
follow-up from the currently available randomized trials would 
be crucial to capture this important information. In addition, 
there is paucity of data on the actual protective effect of GnRHa 
AUTHORS INCLUDED DISEASES 





MAIN RESULTS (GNRHA VS 
CONTROL)
PROTECTION
Bai et al79 Ovarian cancer 15 (1540)d  • POI rate: 23% vs 43%; OR 1.36, 95% CI 
1.19-1.56
 • Pregnancies: 34 (7%) vs 19 (4%); OR 
1.90, 95% CI 1.06-3.41
YES
Senra et al80 HL and NHL 13 (1208)  • POI rate: 20% vs 34%; RR 0.60, 95% CI 
0.45-0.79
 • Pregnancies: 57 (11%) vs 42 (8%); RR 
1.43, 95% CI 1.01-2.02
YES
Hickman et al81 Ovarian cancer, HL and 
NHL
10 (1051)  • POI rate: 29% vs 39%; OR 1.83, 95% CI 
1.34-2.49
YES
Lambertini et al82 - 5 (873)e  • POI rate: 14% vs 31%; OR 0.38, 95% CI 
0.26-0.57
 • Pregnancies: 37 (10%) vs 20 (6%); IRR 
1.83, 95% CI 1.06-3.15
YES
Abbreviations: CI, confidence interval; GnRHa, gonadotropin-releasing hormone agonist; HL, Hodgkin lymphoma; IRR, incidence rate ratio; NHL, 
non-Hodgkin lymphoma; OR, odds ratio; POI, premature ovarian insufficiency; RCT, randomized clinical trial; RR, relative risk/risk ratio/rate ratio.
aFive out of 16 were RCTs
bThree out of 11 were RCTs
cData from breast cancer patients with hormone receptor-negative disease only.
dData from the original publication37 and the updated analysis44 of the PROMISE-GIM6 trial were considered twice instead of as from the same 
study.
eMeta-analysis based on individual patient-level data.
Table 2. (Continued)
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treatment on patients’ ovarian reserve. A prospective study 
including 88 premenopausal breast cancer patients has recently 
shown that antral follicle count recovered faster and to a 
greater degree among women who received GnRHa during 
chemotherapy.97 Nevertheless, so far, data on the dynamic 
of anti-mullerian hormone (AMH, a promising biomarker of 
chemotherapy-induced gonadal damage98–101) during and after 
treatment are limited and mostly negative. Specifically, among 
the breast cancer trials with available information on patients’ 
hormonal profile, only a minority evaluated post-treatment 
AMH, which did not differ between women who received 
chemotherapy alone or with concurrent administration of 
GnRHa.35,39,45 In women with hematological malignancies, the 
only exception was the trial by Demeestere and colleagues that 
showed higher post-treatment AMH levels in patients who 
received GnRHa during chemotherapy at 1-year follow-up 
(P = .040),87 but no difference after 5 years (P = .520).88 Ongoing 
prospective studies are currently investigating the hormonal 
profile including AMH in women receiving temporary ovarian 
suppression with GnRHa during chemotherapy.102–104
Fourth, particularly important for breast cancer patients, 
there is lack of data on the efficacy and safety of temporary 
ovarian suppression with GnRHa during chemotherapy in 
patients with hereditary cancer syndromes, such as those with 
pathogenic germline BRCA mutations.105 To our knowledge, 
the only piece of information on this regard derives from the 
case series by Wong and colleagues in which out of 4 BRCA-
mutated breast cancer patients receiving GnRHa during 
chemotherapy, 3 resumed menstrual function before undergo-
ing prophylactic gynecological surgery.106 Preclinical evidence 
suggests that the presence of BRCA mutations can be associ-
ated with decreased ovarian reserve as well as increased risk of 
fertility-related problems and primary ovarian insufficiency.105 
In breast cancer patients, although not confirmed by other 
studies,107–109 some of the available data suggest the possible 
presence of reduced baseline ovarian reserve in BRCA-mutated 
patients with subsequent potential higher risk of developing 
chemotherapy-induced POI and reduced efficacy of fertility 
preservation procedures.110–112 To acquire evidence on the pro-
tective effect of GnRHa administration during chemotherapy 
in this setting within the currently available randomized clini-
cal trials would be of particular importance. However, these 
women are candidates to receive prophylactic gynecological 
surgery before the age of 40-45 years due to the significant risk 
of developing ovarian cancer.113 Therefore, temporary ovarian 
suppression with GnRHa during chemotherapy is not an opti-
mal strategy in this setting, and it should be offered only to 
women diagnosed years before the age of recommended pro-
phylactic gynecological surgery.105
Conclusions
More than 30 years have passed since the publication of the 
first preclinical data suggesting a possible protective role of 
administering GnRHa during chemotherapy in order to 
preserve ovarian function and potential fertility in premeno-
pausal cancer patients through systemic cytotoxic therapy.29 
In the last years, results from the largest randomized clinical 
trials conducted to assess the efficacy and safety of this 
strategy in premenopausal women with newly diagnosed 
early breast cancer have supported its protective role.43-
45,76,82 Therefore, recent guidelines support the use of tem-
porary ovarian suppression with GnRHa during 
chemotherapy in this setting.16,18,28 Indeed, this strategy is 
now available and covered in many countries.28,114,115
Premenopausal patients interested in reducing the risk of 
developing chemotherapy-induced POI are the best candi-
dates for this strategy irrespectively of their pregnancy desire 
and their age at diagnosis. In other words, temporary ovarian 
suppression with GnRHa during chemotherapy should be 
considered a standard strategy for ovarian function preserva-
tion in breast cancer patients. This strategy will impact on 
reducing the risk of menopausal signs and symptoms includ-
ing loss of bone density in the long-term; these are issues of 
crucial importance also in premenopausal patients including 
women not interested in conceiving after treatment or not 
candidates to fertility preservation strategies because they are 
older than 40 years at diagnosis.
On the other hand, the role of this option as a strategy for 
fertility preservation is to be considered with more caution. In 
fact, although the most recent studies showed a significantly 
higher number of post-treatment pregnancies in the group of 
women who received GnRHa during chemotherapy,43,76,82 
more limited data are available as compared to those on POI so 
that no strong conclusions on this endpoint can be drawn to 
date. Therefore, in these patients, gamete cryopreservation 
remains the first option to be discussed, but temporary ovarian 
suppression with GnRHa during chemotherapy should be also 
proposed following this strategy or to women who have no 
access, refuse, or have contraindications to surgical fertility 
preservation techniques. For women who receive gamete cryo-
preservation followed by temporary ovarian suppression with 
GnRHa during chemotherapy, the type of agent to be used and 
the best timing for GnRHa administration (considering its 
potential use as trigger of follicular maturation instead of cho-
rionic gonadotropin or short-acting GnRHa)82 are important 
to be clarified in the coming years.
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